Corrigendum to: thinking ahead: developing biosynthetic blood to anticipate donor drought
Cell & Gene Therapy Insights 2023; 9(1), 51–52
This corrigendum contains corrections the article ‘Thinking ahead: developing biosynthetic blood to anticipate donor drought’ Cell & Gene Therapy Insights 2022; 8(11), 1561–1570; DOI: 10.18609/cgti.2022.227. In the version of this article initially published, it was stated that clinical trials for Hemarina M101 had been suspended. In fact, at the time of publication, Hemarina’s HEMO2life® had just received CE approval for the preservation of kidney grafts for transplantation. The correction is listed in full below, and the amended article can be accessed here.